The Drug Enforcement Administration (DEA) has published a final rule with technical changes to regulations governing the use of DEA Form 222 to order Schedule I and II controlled substances. This rule became effective on March 20, 2026. It does not add new substantive requirements; rather, it clarifies and corrects previous regulatory rules to eliminate the uncertainty and ensure consistency. These modifications build on an earlier rule issued on September 30, 2019, which introduced a single sheet format for the DEA Form 222. This replaced the older triplicate form and provided registrants with a two-year transition period. The current rule focuses on refining provisions that were inaccurate or inconsistent during the earlier regulatory framework.
The Controlled Substances Act (CSA) provides the legal authority for these regulations, allowing the Attorney General to establish rules regarding the control, registration, manufacturing, distribution, and dispensing of controlled substances, as well as recordkeeping and reporting requirements. This authority has been delegated to the DEA Administrator. The role of agency includes ensuring that the systems used to order and track controlled substances are secure and resistant to diversion, which is the illegal redirection of drugs from legitimate sources to illicit use. DEA Form 222 plays an important role in transactions involving the most strictly controlled substances under federal law.
The execution and revocation of a power of attorney (POA) for DEA Form 222 is a crucial part of these regulations. Under existing regulations, registrants like pharmacies, hospitals, or distributors may authorize individuals to order controlled substances on their behalf by a POA. The 2019 rule restricted who could grant or revoke such authority, specifying that only a registrant, a partner in a partnership, or a corporate officer could perform these actions. However, certain regulatory sections were not updated due to administrative oversight. Some sections still allowed individuals who had signed the most recent DEA registration application to revoke a POA, creating inconsistencies with the intended stricter standards.
This final rule resolves those inconsistencies by updating the affected sections to align with the stricter requirements. Now, only a registrant, partner, or corporate officer may grant or revoke a POA for DEA Form 222. This modification improves regulatory clarity and strengthens protections against misuse of authority. It also reflects the DEA’s commitment to reducing diversion risks associated with improper access to controlled substances.
The DEA has also clarified and removed outdated references to the triplicate version of DEA Form 222 in the regulatory text. These forms became obsolete following the transition to the single-sheet format in 2019, and they were no longer accepted after October 30, 2021. Removing these references simplifies the regulations and reduces potential confusion.
The rule was issued without a public comment process because it imposes no new obligations. It is classified as a non-significant regulatory action under the Executive Order 12866 and as a non-substantive technical correction under the Administrative Procedure Act.
Importantly, this rule does not introduce any new reporting, recordkeeping, or compliance burdens for the registrants. It does not affect any existing information collection approvals under the Paperwork Reduction Act. It does not create any new criminal regulatory violations or change any useful landscape. The main aim of this rule is to improve the clarity, consistency, and serviceability of DEA regulations to support compliance and reduce errors or misinterpretations.
Overall, this final rule represents an effort to correct the technical inconsistencies in the regulations of DEA Form 222. It strengthens the regulatory integrity by reducing the administrative complexity, eliminating outdated sections, and clearly clarifying who is allowed to issue, revoke, or exercise authority to order Schedule I and II controlled substances. The regulatory framework remains aligned with its original intent to safeguard controlled substances distribution and prevent diversion without imposing any additional burdens on registrants.
Reference: Drug Enforcement Administration. Ordering Schedule I and II controlled substances using the DEA Form 222; technical amendments. Fed Regist. 2026;91(54):13498-13500. Ordering Schedule I and II controlled substances using DEA Form 222; technical amendments
